ArticleImmunotherapy advances2026
Optimized procurement of cancer-reactive T-cell receptors from clinical samples.
Article in Immunotherapy advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
T-cell receptors can sense cancer-associated changes in cellular proteins, lipids, metabolites, and stress pathways, enabling immune-mediated tumour elimination in some patients. These receptors underpin T-cell receptor-based immunotherapies, yet their isolation from clinical samples remains challenging due to labour-intensive workflows, dependence on prior antigen knowledge, and loss of cell viability. We developed an optimized flow cytometry-based assay, termed the T107 assay, to isolate viable cancer-reactive T-cells directly from clinical samples. Following short-term exposure to cancer cells, responding T-cells are identified by simultaneous surface detection of tumour necrosis factor and the degranulation marker CD107a, enabling recovery of live antigen-reactive cells for downstream analysis. The T107 assay enabled rapid identification of cancer-reactive T-cells from tumour-infiltrating lymphocyte products derived from melanoma and sarcoma patients. The assay supported phenotypic and functional characterization of αβ and γδ T-cell receptor populations, including CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.